Relationships Between Alexithymia and Psychopathy in Heroin Dependent Individuals.
alexithymia
emotion processing
opioid use disorder
psychopathy
substance use disorders
Journal
Frontiers in psychology
ISSN: 1664-1078
Titre abrégé: Front Psychol
Pays: Switzerland
ID NLM: 101550902
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
01
2019
accepted:
23
09
2019
entrez:
26
10
2019
pubmed:
28
10
2019
medline:
28
10
2019
Statut:
epublish
Résumé
Psychopathy and substance use disorders are highly co-morbid and their co-occurrence is associated with higher severity of addictive behavior and increased risk of violent offending. Both substance use disorders and psychopathy are related to prominent impairments in emotion processing, which are also central features of alexithymia. The nature of the relationship between psychopathy and alexithymia is not well-understood and has been particularly understudied among substance dependent individuals. Our goal was to evaluate the levels of psychopathy and alexithymia in a relatively homogeneous sample of heroin dependent individuals (HDIs) and healthy controls and to examine group differences in the pattern of associations between these constructs. We examined 62 participants (31 heroin dependent individuals and 31 healthy controls) with the Psychopathy Checklist: Screening version (PCL:SV, Hart et al., 1995) and the Toronto Alexithymia Scale-20 (TAS-20, Bagby et al., 1994). Heroin dependent individuals were characterized by higher levels of both psychopathy and alexithymia as compared to the control group. In addition, HDIs with higher levels of psychopathy reported more difficulties in identifying and verbalizing emotional states. In the heroin group, alexithymia was more strongly associated with the impulsive/antisocial characteristics (impulsivity, irresponsibility, antisocial behavior) than with the interpersonal/affective features of psychopathy (grandiosity, manipulativeness, lack of empathy, and remorse). Our findings suggest that alexithymia may be one potential mechanism linking psychopathy with opioid use disorders. The development of interventions targeting alexithymia could have significant applications in relapse prevention programs and psychotherapy of substance use disorders with concurrent psychopathy.
Sections du résumé
BACKGROUND
BACKGROUND
Psychopathy and substance use disorders are highly co-morbid and their co-occurrence is associated with higher severity of addictive behavior and increased risk of violent offending. Both substance use disorders and psychopathy are related to prominent impairments in emotion processing, which are also central features of alexithymia. The nature of the relationship between psychopathy and alexithymia is not well-understood and has been particularly understudied among substance dependent individuals.
AIM
OBJECTIVE
Our goal was to evaluate the levels of psychopathy and alexithymia in a relatively homogeneous sample of heroin dependent individuals (HDIs) and healthy controls and to examine group differences in the pattern of associations between these constructs.
METHODS
METHODS
We examined 62 participants (31 heroin dependent individuals and 31 healthy controls) with the Psychopathy Checklist: Screening version (PCL:SV, Hart et al., 1995) and the Toronto Alexithymia Scale-20 (TAS-20, Bagby et al., 1994).
RESULTS
RESULTS
Heroin dependent individuals were characterized by higher levels of both psychopathy and alexithymia as compared to the control group. In addition, HDIs with higher levels of psychopathy reported more difficulties in identifying and verbalizing emotional states. In the heroin group, alexithymia was more strongly associated with the impulsive/antisocial characteristics (impulsivity, irresponsibility, antisocial behavior) than with the interpersonal/affective features of psychopathy (grandiosity, manipulativeness, lack of empathy, and remorse).
CONCLUSION
CONCLUSIONS
Our findings suggest that alexithymia may be one potential mechanism linking psychopathy with opioid use disorders. The development of interventions targeting alexithymia could have significant applications in relapse prevention programs and psychotherapy of substance use disorders with concurrent psychopathy.
Identifiants
pubmed: 31649591
doi: 10.3389/fpsyg.2019.02269
pmc: PMC6794427
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2269Subventions
Organisme : NIDA NIH HHS
ID : R01 DA021421
Pays : United States
Informations de copyright
Copyright © 2019 Psederska, Savov, Atanassov and Vassileva.
Références
Psychol Addict Behav. 2000 Sep;14(3):243-56
pubmed: 10998950
Psychophysiology. 1994 Jul;31(4):319-30
pubmed: 10690912
J Psychopathol Behav Assess. 2014 Sep 1;36(3):389-400
pubmed: 25313268
Dev Psychopathol. 2012 Aug;24(3):1091-103
pubmed: 22781873
PLoS One. 2017 May 25;12(5):e0177982
pubmed: 28542508
Psychol Rev. 2004 Jan;111(1):33-51
pubmed: 14756584
J Pers Soc Psychol. 1995 Nov;69(5):990-1005
pubmed: 7473043
Addict Behav. 2019 Mar;90:222-228
pubmed: 30447514
Int J Law Psychiatry. 1999 Jan-Feb;22(1):91-7
pubmed: 10086294
J Psychosom Res. 2001 May;50(5):255-61
pubmed: 11399282
Nat Rev Neurosci. 2011 Oct 05;12(11):685-700
pubmed: 21971065
Am J Psychiatry. 1948 Mar;104(9):523-34
pubmed: 18911629
Psychol Psychother. 2011 Mar;84(1):84-97; discussion 98-110
pubmed: 22903833
Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Feb;3(2):141-149
pubmed: 29529409
Neurosci Biobehav Rev. 2015 Aug;55:594-611
pubmed: 26054794
Am J Drug Alcohol Abuse. 2016 Mar;42(2):231-41
pubmed: 26837332
J Affect Disord. 2018 Aug 1;235:265-276
pubmed: 29660642
Clin Psychol Rev. 2013 Dec;33(8):1010-24
pubmed: 24029221
Psychother Psychosom. 1973;22(2):255-62
pubmed: 4770536
J Pers. 2000 Dec;68(6):1059-88
pubmed: 11130732
Law Hum Behav. 2010 Apr;34(2):150-63
pubmed: 19390956
Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):3302-3307
pubmed: 29531085
Br J Clin Psychol. 2018 Jun;57(2):186-202
pubmed: 29277906
Neuron. 2008 Jul 10;59(1):11-34
pubmed: 18614026
Neuropsychopharmacology. 2010 Jan;35(1):217-38
pubmed: 19710631
Subst Use Misuse. 2009;44(9-10):1415-33
pubmed: 19938925
Neuropsychopharmacology. 2014 Jan;39(2):254-62
pubmed: 24121188
Addict Behav. 2009 Dec;34(12):1042-55
pubmed: 19683400
J Psychosom Res. 1994 Jan;38(1):23-32
pubmed: 8126686
Compr Psychiatry. 1994 Mar-Apr;35(2):124-8
pubmed: 8187475
J Abnorm Psychol. 2002 Aug;111(3):411-24
pubmed: 12150417
Psychol Assess. 2004 Sep;16(3):276-88
pubmed: 15456383
Drug Alcohol Depend. 2004 Dec 7;76(3):297-304
pubmed: 15561480
J Anxiety Disord. 2012 Apr;26(3):453-8
pubmed: 22366447
Neurosci Biobehav Rev. 2012 Nov;36(10):2288-304
pubmed: 22944264
Psychiatry Res. 2018 Nov;269:625-632
pubmed: 30208352
PLoS One. 2016 Dec 21;11(12):e0168354
pubmed: 28002494
Front Psychol. 2014 Aug 12;5:849
pubmed: 25161631
Drug Alcohol Depend. 2011 Apr 1;114(2-3):194-200
pubmed: 21112701
Addict Behav. 2018 Feb;77:232-246
pubmed: 29107201
Front Psychol. 2013 Nov 19;4:861
pubmed: 24312069
J Abnorm Psychol. 1990 Nov;99(4):430-9
pubmed: 2266219
Compr Psychiatry. 2014 Oct;55(7):1580-6
pubmed: 25081732
Cognition. 1995 Oct;57(1):1-29
pubmed: 7587017
Clin Psychol Rev. 2007 Dec;27(8):904-22
pubmed: 17343965
Drug Alcohol Depend. 2015 Jul 1;152:157-63
pubmed: 25982006
Drug Alcohol Rev. 2007 Jan;26(1):17-23
pubmed: 17364832
Curr Addict Rep. 2016 Jun;3(2):239-248
pubmed: 27695665
Encephale. 2004 May-Jun;30(3):201-11
pubmed: 15235517
Drug Alcohol Depend. 2007 Jan 12;86(2-3):139-46
pubmed: 16806737
Soc Cogn Affect Neurosci. 2014 Apr;9(4):505-12
pubmed: 23386739
Psychother Psychosom. 2006;75(1):25-39
pubmed: 16361872
J Addict Dis. 2004;23(2):109-22
pubmed: 15132346
Pain Med. 2010 Jul;11(7):1092-8
pubmed: 20545871
Mol Psychiatry. 2009 Jan;14(1):5-6
pubmed: 19096450
Aggress Behav. 2019 May;45(3):265-274
pubmed: 30699249
Law Hum Behav. 2003 Jun;27(3):299-313
pubmed: 12794966
J Pers Disord. 2005 Aug;19(4):339-56
pubmed: 16178678
J Clin Psychiatry. 2006;67 Suppl 7:5-9
pubmed: 16961418
Biol Psychiatry. 2001 Nov 1;50(9):677-84
pubmed: 11704074
Drug Alcohol Depend. 2007 Jan 12;86(2-3):287-9
pubmed: 16930861
Drug Alcohol Depend. 2016 Apr 1;161:247-57
pubmed: 26905209
Indian J Psychol Med. 2017 Sep-Oct;39(5):627-633
pubmed: 29200559
J Psychosom Res. 2005 Mar;58(3):299-306
pubmed: 15865955
Psychiatry Res. 2003 Aug 1;119(3):251-60
pubmed: 12914896
Biol Psychiatry. 2010 Jan 1;67(1):66-70
pubmed: 19793581
Biol Psychiatry. 2016 Aug 1;80(3):179-89
pubmed: 26772405
J Consult Clin Psychol. 2009 Aug;77(4):633-44
pubmed: 19634957
Drug Alcohol Depend. 1998 Feb 1;49(3):217-23
pubmed: 9571386
Annu Rev Psychol. 2008;59:29-53
pubmed: 18154498
J Abnorm Psychol. 1957 Jul;55(1):6-10
pubmed: 13462652
Psychiatry Res. 2011 May 30;187(3):414-7
pubmed: 21377739
Ir Med J. 2010 Jun;103(6):176-9
pubmed: 20669601